CapsoVision announced today that it closed its initial public offering (IPO) and began trading on the Nasdaq Capital Market.
Saratoga, California–based CapsoVision now trades on the Nasdaq under the “CV” ticker as of July 2, 2025. The IPO includes 5.5 million shares of common stock priced at $5 per share.
CapsoVision granted underwriters a 30-day option to purchase up to an additional 825,000 shares of common stock at the offering price. The company reported proceeds of $27.5 million from the IPO before discounts, commissions and other expenses.
With the IPO, CapsoVision joins a handful of medtech companies to go public over the past couple of years. Wearable defibrillator maker Kestra Medical completed a $202 million IPO in March, while Beta Bionics went public in January with a $204 million IPO. Last year, heart valve company Anteris Technologies and neurotech company CeriBell completed IPOs. Additionally, medtech distribution giant Medline submitted a draft registration to the SEC related to a proposed IPO in December and Carlsmed shared its intent to go public last week.
Now public, CapsoVision can continue to advance its AI-based capsule endoscopy technology. The company develops the CapsoCam Plus system, which delivers a non-invasive, comfortable endoscopy in the form of a capsule device. With four cameras, it delivers a 360° panoramic lateral view of the small bowel and any abnormalities in high resolution. This enables physicians to look directly at the mucosa where abnormalities are present, rather than “down the tunnel,” improving visibility of potential lesions.
CapsoCam also features CapsoCloud, the company’s advanced cloud-based software. This enables providers to easily view the diagnostic results online, improving efficiency and reducing procedure time.
The company won FDA clearance for the system earlier this year.
